These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31721805)

  • 1. Cumulative viral load as a predictor of CD4+ T-cell response to antiretroviral therapy using Bayesian statistical models.
    Sempa JB; Rossouw TM; Lesaffre E; Nieuwoudt M
    PLoS One; 2019; 14(11):e0224723. PubMed ID: 31721805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of statistically-derived models of immunological response in HIV-infected adults on antiretroviral therapy in Sub-Saharan Africa.
    Sempa JB; Ujeneza EL; Nieuwoudt M
    PLoS One; 2017; 12(2):e0171658. PubMed ID: 28199360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian inference for a nonlinear mixed-effects Tobit model with multivariate skew-t distributions: application to AIDS studies.
    Dagne G; Huang Y
    Int J Biostat; 2012 Sep; 8(1):. PubMed ID: 22992288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian inference on mixed-effects location scale models with skew-t distribution and mismeasured covariates for longitudinal data.
    Lu T
    Stat Med; 2017 Jul; 36(16):2614-2629. PubMed ID: 28421622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.
    Palacios R; Senise J; Vaz M; Diaz R; Castelo A
    HIV Med; 2009 Mar; 10(3):157-62. PubMed ID: 19245537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral load versus CD4⁺ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study.
    Salazar-Vizcaya L; Keiser O; Karl Technau ; Davies MA; Haas AD; Blaser N; Cox V; Eley B; Rabie H; Moultrie H; Giddy J; Wood R; Egger M; Estill J
    AIDS; 2014 Oct; 28(16):2451-60. PubMed ID: 25392857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous Treatment of Missing Data and Measurement Error in HIV Research Using Multiple Overimputation.
    Schomaker M; Hogger S; Johnson LF; Hoffmann CJ; Bärnighausen T; Heumann C
    Epidemiology; 2015 Sep; 26(5):628-36. PubMed ID: 26214336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
    Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
    Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies.
    Brown ER; MaWhinney S; Jones RH; Kafadar K; Young B
    Stat Med; 2001 Aug; 20(16):2489-504. PubMed ID: 11512138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed-effects joint models with skew-normal distribution for HIV dynamic response with missing and mismeasured time-varying covariate.
    Huang Y; Chen J; Yan C
    Int J Biostat; 2012 Nov; 8(1):. PubMed ID: 23192055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients.
    Vandormael A; Rego F; Danaviah S; Carlos Junior Alcantara L; Boulware DR; de Oliveira T
    Curr HIV Res; 2017; 15(3):225-231. PubMed ID: 28215175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.
    Schultze A; Torti C; Cozzi-Lepri A; Vandamme AM; Zazzi M; Sambatakou H; De Luca A; Geretti AM; Sonnerborg A; Ruiz L; Monno L; Di Giambenedetto S; Gori A; Lapadula G;
    AIDS; 2019 Feb; 33(2):315-326. PubMed ID: 30325769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.